Contract development organisation (CRO) Huasky Medical has garnered $50 million in its Series C round, while Hong Kong-based Chinese CRO firm ZSHK Lab has raised 100 million yuan ($15 million) in its Series A round led by Qiming Venture Partners.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com